A recent 14-day study that compared the efficacy of an allergy spray in 304 children aged 6-11 years with seasonal allergic rhinitis showed that the result depended on who assessed symptoms: children themselves or their caregiver.
Children reported significant improvement in their symptoms when they received MP-AzeFlu (Dymista®) compared with placebo. Caregivers, on the other hand, where unable to accurately gauge the severity of symptoms on their children's behalf.
"Symptom severity assessment by caregivers and children cannot be assumed to be the same. In fact, caregivers are less sensitive than children in assessing response to treatment, at least with available tools," said Dr. William Berger, lead author of the Pediatric Allergy and Immunology study. "In this regard children, and not caregivers, appear to know best!"
Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, Nieto A, Valovirta E, Wickman M, Bousquet J. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment. Pediatr Allergy Immunol 2016: 27: 126-133.
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.